Inside Precision Medicine March 25, 2024
Mirador Therapeutics has launched with more than $400 million through a financing led by ARCH Venture Partners. The start-up aims to “revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases,” according to their release. They aim to do this by leveraging their proprietary Mirador360 development engine to rapidly advance multiple programs in drug discovery and diagnostics.
Mirador360 is a repository of immune-mediated disease data. The company says the platform is “purpose-built to harmonize millions of patient molecular profiles to discover and validate genetic associations to immuno-fibrotic diseases, identify novel therapeutic targets and elucidate target-target interactions as well as optimal target-target pairs for potential combination therapies.”
The start-up was founded by Mark C. McKenna and led by several former executives of...
Today's Sponsors
Today's Sponsor